Search

PPV is immunogenic in 9-month-old children at high risk of pneumococcal infections and does not affect the capacity to produce protective immune responses

Pneumonia is the leading cause of childhood morbidity and mortality globally.

decreased serum IgG responses to NTHi outer membrane proteins may contribute to the development of chronic and severe OM in Australian Aboriginal children

Intranasal vaccines offer a needle-free strategy to enhance immunity to respiratory infections. We investigated the mechanism of action of a novel intranasal vaccine using the human respiratory commensal Haemophilus haemolyticus, previously shown to protect against nontypeable Haemophilus influenzae otitis media and accelerate clearance of influenza A virus.

The Bacterial Respiratory Infectious Disease Group (BRIDG) has a major focus ear and lung disease involving Streptococcus pneumoniae and Haemophilus influenzae.

Co-Head, Bacterial Respiratory Infectious Disease Group; Microbiology Lead, Wesfarmers Centre of Vaccines & Infectious Diseases

Co-head, Bacterial Respiratory Infectious Disease Group (BRIDG)

Peter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group

Peter Lea-Ann Ruth Richmond Kirkham Thornton MBBS MRCP(UK) FRACP PhD PhD Head, Vaccine Trials Group Co-Head, Bacterial Respiratory Infectious Disease

Janessa Lea-Ann Peter Ruth Pickering Kirkham Richmond Thornton BSc PhD PhD MBBS MRCP(UK) FRACP PhD Senior Research Fellow Co-Head, Bacterial